Sanglifehrin A, a Novel Cyclophilin-Binding Compound Showing Immunosuppressive Activity with a New Mechanism of Action

摘要

We report here on the characterization of the novel immunosuppressant Sanglifehrin A( SFA).SFA is a representative of a class of macrolides produced by actinomycetes that bind to cyclophilin A(CypA),the binding protein of the fungal cyclic peptide cyclosporin A(CsA).SFA interacts with high affinity with the CsA binding side of CypA and inhibits its peptidyl-prolyl isomerase activity.The mode of action of SFA is different from known immunosuppressive drugs.It has no effect on the phosphatase activity of calcineuring,the target of the immunosuppressants CsA and FK506 when complexed to their binding proteins CpyA and FK binding protein,respectively.Moreover,its effects are independent of binding of cyclophilin.SFA does not affect IL-2 transcription or secretion.However,it blocks IL-2-dependent proliferation and cytokine production of T cells,in this respect resembling rapamycin.SFA inhibits the proliferation of mitogen-activated B cells,but,unlike rapamycin,it has no effect on CD154/IL-4-induced Ab synthesis.The activity of SFA is also different from that of other known late-acting immunosuppressants,e.g., mycophenolate mofetil or brequinar,as it does not affect de novo purine and pyrimidine biosynthesis.In summary,we have identified a novel immunosuppressant,which represents,in addition to CsA,FK506 and rapamycin, a fourth class of immunophilin-binding metabolites with a new,yet undefined mechanism of action.